Terapet is a technology company.
Terapet has raised $2.0M across 1 funding round.
Terapet has raised $2.0M in total across 1 funding round.
Terapet SA is a Geneva-based MedTech company and CERN spin-off that develops and manufactures innovative gamma-ray detection systems for nuclear medicine imaging and radiotherapy.[1][2][3] It builds products like Qualyscan (in commercialization for patient-specific quality assurance in proton and carbon ion therapy) and Nuclyscan (R&D-stage total-body PET scanner for theranostic applications), serving hospitals, pharmaceutical companies, research centers, and proton therapy facilities.[1][2][3] These solutions address precision challenges in cancer treatment by enabling end-to-end quality control, treatment optimization, and accelerated precision medicine deployment.[1][3][4]
Terapet solves key problems in proton therapy and nuclear imaging, such as ensuring treatment accuracy and tracing biochemical relapses in cancers like prostate and breast, with strong growth momentum including Venture Kick success on June 13, 2025, and plans for Nuclyscan delivery in 2026 via Series B proceeds.[1][2]
Terapet SA was incorporated in Geneva, Switzerland, on December 19, 2019, as a CERN MedTech spin-off leveraging novel gamma-ray detection technology.[2][3] The founders are Dr. Christina Vallgren (PhD in Applied Physics, MSc in Nuclear Physics, MBA), Dr. Marcus Palm (PhD in Applied Physics, MSc in Engineering Physics and Electronics, CTO who pitched at Swiss Innovation Challenge 2019 Top 10), and Prof. Raymond Miralbell (Radiation Oncologist with 40+ years in prostate/breast cancer, proton therapy, and image-guided radiotherapy).[1][2]
The idea emerged from CERN research in nuclear imaging, evolving into a platform for proton therapy quality assurance (Qualyscan) and PET scanning (Nuclyscan), with early traction via Venture Kick funding and participation in Europe's Theranostic Trial Alliance.[1][2] Pivotal moments include 2022 Innosuisse events and 2025 commercialization milestones.[1]
Terapet rides the precision oncology wave, capitalizing on rising proton therapy adoption and theranostics—combining diagnostics and therapy for personalized cancer care.[1][3] Timing is ideal amid growing demand for advanced nuclear imaging, driven by carbon ion therapy expansion and post-2020 MedTech investments in AI-integrated diagnostics.[1][2]
Market forces like Europe's clinical trial networks and Switzerland's MedTech hub (e.g., CERN innovation pipeline) favor Terapet, positioning it to influence proton therapy standards and reduce treatment errors.[1][3] It advances the ecosystem by enabling "quality and new clinical nuclear imaging" in every diagnosis, bridging research to routine precision medicine.[3]
Terapet is poised for Series B-fueled scale, with Nuclyscan launching in 2026 to dominate theranostic PET imaging and expand Qualyscan globally.[1][3] Trends like AI-enhanced radiotherapy and personalized proton/carbon therapies will propel growth, potentially evolving Terapet into a precision medicine leader via pharma partnerships and hospital adoptions.[1][2]
Its CERN roots and alliance integrations suggest expanding influence, transforming cancer outcomes from reactive to predictive—reinforcing its role as a high-momentum MedTech innovator in nuclear imaging.[1][3]
Terapet has raised $2.0M in total across 1 funding round.
Terapet's investors include Blumberg Capital, Nina Capital.
Terapet has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $2.0M Seed | Blumberg Capital, Nina Capital |